Effect of photodynamic therapy on the extracellular matrix and associated components

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 8, 2007, Pages 1025-1035

  Pazos, Marcelo D C ^a   Nader, H B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adhesion; Chemical mediators; Extracellular matrix; Matrix metalloproteinases; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; COLLAGEN FIBER; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; DENDRITIC CELL VACCINE; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEMATOPORPHYRIN; HEXYLPYROPHEOPHORBIDE; HYPERICIN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; METHYLENE BLUE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PHEOPHORBIDE; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE ZINC; POLYHEMATOPORPHYRIN; PROSTANOID; PROTOPORPHYRIN; REACTIVE OXYGEN METABOLITE; SELECTIN; TETRAPHENYLPORPHYRIN; UNINDEXED DRUG; UVOMORULIN; VASCULAR CELL ADHESION MOLECULE 1;

BREAST CARCINOMA; CANCER INHIBITION; CELL ADHESION; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME ANALYSIS; EXTRACELLULAR MATRIX; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; IONIZING RADIATION; LEUKOCYTE ACTIVATION; LIGHT ABSORPTION; LIGHT EXPOSURE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROTEIN FUNCTION; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SQUAMOUS CELL CARCINOMA; ULTRAVIOLET RADIATION; VASCULAR TUMOR;

EID: 34547787633     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2006005000142     Document Type: Review

References (59)

1. Dougherty TJ. An update on photodynamic therapy applications. J Clin Laser Med Surg 2002; 20: 3-7.
2. Hay ED. Cell biology of the extracellular matrix. 2nd edn. New York: Plenum Press; 1991.
3. van Duijnhoven FH, Aalbers RI, Rovers JP, Terpstra OT, Kuppen PJ. The immunological consequences of photodynamic treatment of cancer, a literature review. Immunobiology 2003; 207: 105-113.
4. Runnels JM, Chen N, Ortel B, Kato D, Hasan T. BPD-MA-mediated photosensitization in vitro and in vivo. cellular adhesion and beta1 integrin expression in ovarian cancer cells. Br J Cancer 1999; 80: 946-953.
5. Yamada KM, Pankov R, Cukierman E. Dimensions and dynamics in integrin function. Braz J Med Biol Res 2003; 36: 959-966.
6. Margaron P, Sorrenti R, Levy JG. Photodynamic therapy inhibits cell adhesion without altering integrin expression. Biochim Biophys Acta 1997; 1359: 200-210.
7. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 1992; 52: 4914-4921.
8. Dellian M, Abels C, Kuhnle GE, Goetz AE. Effects of photodynamic therapy on leucocyte-endothelium interaction: differences between normal and tumour tissue. Br J Cancer 1995; 72: 1125-1130.
9. Sluiter W, de Vree WJ, Pietersma A, Koster JF. Prevention of late lumen loss after coronary angioplasty by photodynamic therapy: role of activated neutrophils. Mol Cell Biochem 1996; 157: 233-238.
10. Gollnick SO, Evans SS, Baumann H, Owczarczak B, Maier P, Vaughan L, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer 2003; 88: 1772-1779.
11. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two-cellular signaling, cell metabolism and modes of cell death. Photodiagn Photodyn Ther 2005; 2: 1-23.
12. Volanti C, Gloire G, Vanderplasschen A, Jacobs N, Habraken Y, Piette J. Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene 2004; 23: 8649-8658.
13. Jiang F, Chopp M, Katakowski M, Cho KK, Yang X, Hochbaum N, et al. Photodynamic therapy with photofrin reduces invasiveness of malignant human glioma cells. Lasers Med Sci 2002; 17: 280-288.
14. Vonarx V, Foultier MT, Xavier de BL, Anasagasti L, Morlet L, Patrice T. Photodynamic therapy decreases cancer colonic cell adhesiveness and metastatic potential. Res EXP Med 1995; 195: 101-116.
15. Cavallaro U, Christofori G. Multitasking in tumor progression: signaling functions of cell adhesion molecules. Ann N Y Aced Sci 2004; 1014: 58-66.
16. Uzdensky AB, Juzeniene A, Kolpakova E, Hjortland GO, Juzenas P, Moan J. Photosensitization with protoporphyrin IX inhibits attachment of cancer cells to a substratum. Biochem, Biophys Res Commun 2004; 322: 452-457.
17. Ball DJ, Mayhew S, Vernon DI, Griffin M, Brown SB. Decreased efficiency of trypsinization of cells following photodynamic therapy: evaluation of a role for tissue transglutaminase. Photochem Photobiol 2001; 73: 47-53.
18. Johnson TS, Knight CR, el-Alaoui S, Mian S, Rees RC, Gentile V, et al. Transfection of tissue transglutaminase into a highly malignant hamster fibrosarcoma leads to a reduced incidence of primary tumour growth. Oncogene 1994; 9: 2935-2942.
19. Uzdensky A, Juzeniene A, Ma LW, Moan J. Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum. Biochim Biophys Acta 2004; 1670: 1-11.
20. Fungaloi P, Statius van Eps R, Wu YP, Blankensteijn J, de Groot P, van Uurk H, et al. Platelet adhesion to photodynamic therapy-treated extracellular matrix proteins. Photochem Photobiol 2002; 75: 412-417.
21. de Vree WJ, Fontijne-Dorsman AN, Koster JF, Sluiter W. Photodynamic treatment of human endothelial cells promotes the adherence of noutrophils in vitro. Br J Cancer 1996; 73: 1335-1340.
22. Lopes CC, Dietrich CP, Nader HB. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling. Braz J Med Biol Res 2006; 39: 157-167.
23. Taylor KR, Gallo RL. Glycosaminoglycans and their proteoglycans: host-associated molecular patterns for initiation and modulation of inflammation. FASEB J 2006; 20: 9-22.
24. Heckenkamp J, Adili F, Kishimoto J, Koch M, Lamuraglia GM. Local photodynamic action of mothylene blue favorably modulates the postinterventional vascular wound healing response. J Vasc Surg 2000; 31: 1168-1177.
25. Wight TN. Versican: a versatile extracellular matrix proteoglycan in call biology. Curr Opin Cell Biol 2002; 14: 617-623.
26. Yom SS, Busch TM, Friedberq JS, Wileyto EP, Smith D, Glatstein E, et al. Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy. Photochem Photobiol 2003; 78: 75-81.
27. Kick G, Messer G, Plewig G, Kind P, Goetz AE. Strong and prolonged induction of c-jun and c-fos proto-oncogenes by photodynamic therapy. Br J Cancer 1996; 74: 30-36.
28. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997; 57: 3904-3909.
29. Du H, Bay BH, Mahendran R, Olivo M. Hypericin-mediated photodynamic therapy elicits differential interleukin-6 response in nasopharyngeal cancer. Cancer Lett 2006; 235: 202-208.
30. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kassel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
31. Gollnick SO, Vaughan L, Henderson BW. Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res 2002; 62: 1604-1608.
32. Korbelik M, Sun J. Photodynamic therapy-generated vaccine for cancer therapy. Cancer Immunol Immunother 2006; 55: 900-909.
33. Jee SH, Shen SC, Chiu HC, Tsai WL, Kuo ML. Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency. Oncogene 2001; 20: 198-208.
34. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
35. Kinoshita T, Ito H, Miki C. Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer 1999; 85: 2526-2531.
36. Wong TW, Tracy E, Oseroff AR, Baumann H. Photodynamic therapy mediates immediate loss of cellular responsiveness to cytokines and growth factors. Cancer Res 2003; 63: 3812-3818.
37. Agostinis P, Assefa Z, Vantieghem A, Vandenheede JR, Merievede W, De Witte P. Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv Enzyme Regul 2000; 40: 157-182.
38. Spaulding DC, Spaulding BO. Epidermal growth factor receptor expression and measurement in solid tumors. Semin Oncol 2002; 29: 45-54.
39. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999; 82: 207-218.
40. Ahmad N, Kalka K, Mukhtar H. In vitro and in vivo inhibition of epidermal growth factor receptor-tyrosine kinase pathway by photo-dynamic therapy. Oncogene 2001; 20: 2314-2317.
41. Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothellal growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480.
42. Duh EJ, Yang HS, Suzuma I, Miyagi M, Youngman E, Mori K, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
43. Ferrario A, von Tiehl KF, Rucker N, Schwarz MA, Gill PS, Gomer CJ. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60: 4066-4069.
44. Ogata N, Wada M, Otsuji T, Jo N, Tombran-Tink J, Matsumura M. Expression of pigment epithelium-derived factor in normal adult rat eye and experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 2002; 43: 1166-1175.
45. Waterman PR, Overhaus M, Heckenkamp J, Nigri GR, Fungaloi PF, Landis ME, et al. Mechanisms of reduced human vascular cell migration after photodynamic therapy. Photochem Photobiol 2002; 75: 46-50.
46. Bonewald LF. Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr 1999; 9: 33-44.
47. Statius van Eps RG, Adili F, Watkins MT, Anderson RR, Lamuraglia GM. Photodynamic therapy of extracellular matrix stimulates endothelial cell growth by inactivation of matrix-associated transforming growth factor-beta. Lab Invest 1997; 76: 257-266.
48. Heckenkamp J, Aleksic M, Gawenda M, Breuer S, Brabender J, Mahdavi A, et al. Modulation of humam adventitial fibroblast function by photodynamic there of collagen matrix. Eur J Vasc Endovasc Surg 2004; 28: 651-659.
49. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prosta-cyclin release on photodynamic therapy-induced tumor destruction. Cancer Res 1990;.50: 2599-2603.
50. Hendrickx N, Volanti C, Moens U, Setemes OM, De Witte P, Vandenheede JR, et al. Up-regulation of cyclooxygenase-2 and apoptosis resistance by p38 MAPK in hypericin-mediated photodynamic therapy of human cancer cells. J Biol Chem 2003; 278: 52231-52239.
51. Ferrario A, von Tiehl K, Wong S, Luna M, Gomer CJ. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002; 62: 3956-3961.
52. Makowski M, Grzela T, Nideria J, Lazarczyk M, Mroz P, Kopee M, et al. Inhibition of cyclooxygenase-2 indirectly potentiates antitumor effects of photodynamic therapy in mice. Clin Cancer Res 2003; 9: 5417-5422.
53. Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Influence of 5-aminolevulinic acid and red light on collagen metabolism of human dermal fibroblasts. J Invest Dermatol 2003; 120: 325-331.
54. Karrer S, Abels C, Weiderer P, Bosserhoff A, Landthaler M, Szeimies RM. Induction of collagenases in human dermal fibroblasts by 5-aminolevulinic acid and light. Med Laser Appl 2001; 16: 148 (Abstract).
55. Karrer S, Bosserhoff AK, Weiderer P, Landthaler M, Szeimies RM. Keratinocyte-derived cytokines after photodynamic therapy and their paracrine induction of matrix metalloproteinases in fibroblasts. Br J Dermatol 2004; 151: 776-783.
56. Ferrario A, Chantrain CF, von Tiehl K, Buckley S, Rucker N, Shalinsky DR, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004; 64: 2328-2332.
57. Shen HR, Spikes JD, Kopecekova P, Kopecek J. Photodynamic crosslinking of proteins. I. Model studies using histidine- and lysine-containing N-(2-hydroxypropyl)methacrylamide copolymers. J Photochem Photobiol B 1996; 34: 203-210.
58. Overhaus M, Heckenkamp J, Kossodo S, Leszczynski D, Lamuraglia GM. Photodynamic therapy generates a matrix barrier to invasive vascular call migration. Circ Res 2000; 86: 334-340.
59. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 2006; 6: 535-545.